CN Patent

CN104039328B — 对蛋白酶体抑制剂的反应的生物标记

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2018-10-09 · 8y expired

What this patent protects

本文揭示与对蛋白酶体抑制剂治疗的敏感性相关的标记。在肿瘤细胞中的RAS基因是野生型时观察到敏感性。本文进一步提供组合物和方法评价标记基因的标记以预测使用蛋白酶体抑制剂治疗患有实体肿瘤(例如肺肿瘤或结肠肿瘤)的患者的结果。

USPTO Abstract

本文揭示与对蛋白酶体抑制剂治疗的敏感性相关的标记。在肿瘤细胞中的RAS基因是野生型时观察到敏感性。本文进一步提供组合物和方法评价标记基因的标记以预测使用蛋白酶体抑制剂治疗患有实体肿瘤(例如肺肿瘤或结肠肿瘤)的患者的结果。

Drugs covered by this patent

Patent Metadata

Patent number
CN104039328B
Jurisdiction
CN
Classification
—
Expires
2018-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.